The GTA+ve fraction showed a 40% reduction in cell viability at a

The GTA+ve fraction showed a 40% reduction in cell viability at a dose of 80 ug/ml (Figure 3A) while GTA-ve treatment had no effect. Treatment up to 48 hrs using 80 ug/ml showed the same 40% reduction selleck screening library as early as 12 hrs, which dropped further to 70% by 48 hrs (Figure 3B). No effect on cell proliferation was observed with the GTA-ve fraction or vehicle (DMSO). Evidence of apoptotic activity was determined by the detection of poly(ADP-ribose) polymerase (PARP) cleavage products through Western blot (Figure 3C). A number of PARP cleavage products including the hallmark 89 and 24 kDa fragments,

as well as others (Figure 3C), were induced following 48 hrs treatment with GTA+ve fraction, but not with GTA-ve treatment, suggesting a possible pro-apoptotic function of GTAs. Figure 3 Proliferation of SW620 cells treated with GTA+ve and GTA-ve extracts. (A) SW620 cells were incubated with increasing concentrations of GTA+ve and GTA-ve extracts for 24 hours and proliferation Veliparib manufacturer assayed by MTT. (B) The 80 ug/ml concentration

of GTA+ve and GTA-ve extracts was then used to treat cells for up to 48 hours and the effect on cell proliferation assayed by MTT. Data are Ro 61-8048 concentration expressed as percent of vehicle or 0 hrs ± 1S.D. (C) Representative Western blot analysis of caspase-mediated PARP Bay 11-7085 cleavage fragments resulting from treatment with GTA+ve and -ve extracts. Experiments were repeated at least three times. We repeated the studies in MCF7 cells, which upon treatment with GTA+ve fraction showed gross cellular changes visible through phase-contrast microscopy including the appearance of apoptosomes and enlarged nuclei that were not observed with vehicle or GTA-ve treatments (Figures 4A, B and 4C). GTA+ve treatment in MCF-7 cells also resulted in the exclusive induction of the 24

kDa PARP cleavage product relative to vehicle or GTA-ve treatment (Figure 4D), further suggesting a pro-apoptotic activity of GTA-containing extracts. Figure 4 Treatment of MCF7 cells with GTA+ve and GTA-ve extracts. MCF7 cells were incubated with vehicle (A), 80 ug/ml GTA+ve extract (B), and 80 ug/ml GTA-ve extract (C) and cells photographed using phase-contrast light microscopy (200×). (D) Western analysis of PARP cleavage products; ns, non-specific. GTA+ve extracts inhibit pro-inflammatory markers The structural resemblance of GTAs to the inflammation-resolving protectins and resolvins prompted us to investigate the effect of GTA+ve extract on pro-inflammatory markers.

Comments are closed.